Ramírez-García Daniel, Fermín-Martínez Carlos A, Castro Paulina Sánchez, Cortez-Flores Brenda Guadalupe, Espinosa Jerónimo Perezalonso, Díaz-Sánchez Juan Pablo, Carrillo-Herrera Karime Berenice, Cabrera-Quintana Leslie Alitzel, Berumen-Campos Jaime, Kuri-Morales Pablo, Tapia-Conyer Roberto, Seiglie Jacqueline A, Alegre-Díaz Jesus, Antonio-Villa Neftali Eduardo, Bello-Chavolla Omar Yaxmehen
Research Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.
medRxiv. 2025 May 23:2025.05.23.25328234. doi: 10.1101/2025.05.23.25328234.
Accurate estimation of glomerular filtration rate (eGFR) is essential for identifying and managing chronic kidney disease (CKD). The CKD-EPI 2021 equation removed the race coefficient from the 2009 version, but its impact in Mexican populations remains unclear.
To compare eGFR category prevalence and the prognostic performance of the CKD-EPI 2009 and 2021 creatinine-based eGFR equations in Mexican adults.
We evaluated 25,236 adults ≥20 years from the 2016-2023 cycles of the Mexican National Health and Nutrition Survey (ENSANUT) to estimate national CKD and eGFR category prevalence using both equations. We also assessed 10-year all-cause and cardiovascular mortality risk in 143,410 adults from the Mexico City Prospective Study (MCPS) using adjusted Cox regression models.
In ENSANUT 2023, prevalence of eGFR <60mL/min/1.73m2 was lower with CKD-EPI 2021 (2.8% 95%CI 1.47-4.13) compared to 2009 (3.4% 95%CI 1.79-5.01). The 2021 equation resulted in upward reclassification of eGFR in 6.2% of adults, particularly among older adults and those with hypertension or diabetes, yielding a reduction in 496,362 adults identified with eGFR <60mL/min/1.73m compared to the 2009 equation. In MCPS, upward reclassification between eGFR categories occurred in 8.3% of participants, and both equations showed similar discrimination for 10-year all-cause (c-statistics: 0.672 for both) and cardiovascular mortality (0.686 vs. 0.685), with similar performance and calibration.
The CKD-EPI 2021 equation yields lower prevalence of low eGFR but maintains similar predictive accuracy for mortality compared to the 2009 version. Findings support the use of the 2009 equation for population health monitoring in Mexico without compromising prognostic utility.
准确估算肾小球滤过率(eGFR)对于识别和管理慢性肾脏病(CKD)至关重要。CKD-EPI 2021方程去除了2009版中的种族系数,但其在墨西哥人群中的影响仍不明确。
比较CKD-EPI 2009和2021基于肌酐的eGFR方程在墨西哥成年人中eGFR类别患病率及预后表现。
我们评估了来自墨西哥国家健康与营养调查(ENSANUT)2016 - 2023周期的25236名≥20岁的成年人,使用这两个方程来估算全国CKD和eGFR类别患病率。我们还使用校正后的Cox回归模型评估了来自墨西哥城前瞻性研究(MCPS)的143410名成年人的10年全因死亡率和心血管死亡率风险。
在2023年的ENSANUT中,与2009年(3.4%,95%CI 1.79 - 5.01)相比,CKD-EPI 2021方程得出的eGFR<60mL/min/1.73m²的患病率更低(2.8%,95%CI 1.47 - 4.13)。2021方程导致6.2%的成年人eGFR向上重新分类,尤其是在老年人以及患有高血压或糖尿病的人群中,与2009方程相比,被识别为eGFR<60mL/min/1.73m的成年人减少了496362例。在MCPS中,8.3%的参与者出现了eGFR类别之间的向上重新分类,两个方程在10年全因死亡率(c统计量:两者均为0.672)和心血管死亡率(0.686对0.685)方面表现出相似的区分能力,具有相似的表现和校准。
与2009版相比,CKD-EPI 2021方程得出的低eGFR患病率更低,但在死亡率预测准确性方面保持相似。研究结果支持在墨西哥使用2009方程进行人群健康监测,而不影响预后效用。